sildenafil acetate | 255885-47-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: sildenafil acetate
• 英文别名: Sildenafil acetate；acetic acid;5-[2-ethoxy-5-(4-methylpiperazin-1-yl)sulfonylphenyl]-1-methyl-3-propyl-6H-pyrazolo[4,3-d]pyrimidin-7-one
• CAS: 255885-47-3
• 化学式: C₂H₄O₂*C₂₂H₃₀N₆O₄S
• 分子量: 534.637
• InChiKey: LGAWYGLSPQIPLJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  37
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  155
• 氢给体数：
  2
• 氢受体数：
  10

反应信息

• 作为产物：
  描述：

  溶剂黄146 、 西地那非 在 acetate buffer 作用下， 生成 sildenafil acetate
  参考文献：
  名称：

  [EN] FORMULATIONS OF PHOSPHODIESTERASE 5 INHIBITORS AND METHODS OF USE
  [FR] FORMULATIONS D'INHIBITEURS DE LA PHOSPHODIESTERASE 5 ET PROCEDES D'UTILISATION

  摘要：

  本发明提供了一种用于通过向哺乳动物输送磷酸二酯酶5抑制剂来增强性功能障碍或功能低下治疗的组合物和输送方法。磷酸二酯酶抑制剂是用于这种适应症的化合物类的一个例子。该类化合物的例子包括他达拉非、伐地那非和西地那非。此外，本发明提供了用于增强溶液、悬浮液和凝胶配方中西地那非浓度的组合物和输送方法，以及通过肌肉注射、皮下注射、舌下给药、鼻内给药和颊黏膜给药的方法。

  公开号：

  WO2005077374A1

文献信息

• [EN] SAA DERIVATIVE COMPOUND RESTORES ENOS AND INHIBITS OXIDATIVE STRESS-INDUCED DISEASES IN HYPOXIA<br/>[FR] COMPOSÉ DÉRIVÉ DE SAA PERMETTANT LE RÉTABLISSEMENT DE L'ENOS ET INHIBANT LES AFFECTIONS INDUITES PAR LE STRESS OXYDATIF DANS L'HYPOXIE
  申请人：JANSFAT BIOTECHNOLOGY CO LTD

  公开号：WO2015161510A1

  公开（公告）日：2015-10-29

  The Substituted Amine Analogs (SAA) derivative compounds and SAA complex compounds disclosed are characterized as compositions having the functions of inhibiting disorders caused by oxidative stress, and more particularly to those SAA derivative compounds capable of inhibiting disorders caused by oxidative stress consisting of neurodegenerative diseases, lung diseases, oxidative stress-induced heart disease and carvenosus dysfunction.

  所披露的取代胺类似物（SAA）衍生物化合物和SAA复合物化合物被描述为具有抑制由氧化应激引起的疾病的功能的组合物，更特别地是那些能够抑制由氧化应激引起的神经退行性疾病、肺部疾病、氧化应激诱导的心脏疾病和心脏功能障碍的SAA衍生物化合物。
• SAA Derivative Compound Restores eNOS And Inhibits Oxidative Stress-Induced A Diseases In Hypoxia
  申请人：JANSFAT BIOTECHNOLOGY CO., LTD.

  公开号：US20150306107A1

  公开（公告）日：2015-10-29

  The Substituted Amine Analogs (SAA) derivative compounds and SAA complex compounds disclosed in the present invention are characterized as compositions having the functions of inhibiting disorders caused by oxidative stress, and more particularly to those SAA derivative compounds capable of inhibiting disorders caused by oxidative stress because of neurodegenerative diseases, lung diseases, oxidative stress-induced heart disease and carvenosus dysfunction.

  本发明揭示的取代胺类似物（SAA）衍生物化合物和SAA复合物化合物的特征是具有抑制氧化应激引起的疾病的功能，更特别地，是那些能够抑制由于神经退行性疾病、肺部疾病、氧化应激引起的心脏疾病和海绵体功能障碍引起的疾病的SAA衍生物化合物。
• Formulations of phosphodiesterase 5 inhibitors and methods of use
  申请人：Jiang Ge

  公开号：US20060035905A1

  公开（公告）日：2006-02-16

  The present invention provides compositions and delivery methods to enhance treatment for sexual dysfunction or hypofunction through the delivery of phosphodiesterase 5 inhibitors to a mammal. Phosphodiesterase 5 inhibitors are one example of a compound class used for this indication. Examples of compounds in this class include taldalafil and vardenafil and sildenafil. Furthermore, the present invention provides compositions and delivery methods to enhance the sildenafil concentration in solution, suspension and gel formulations and methods of parenteral, intradermal, sublingual, intranasal, and buccal sildenafil delivery.

  本发明提供了一种通过向哺乳动物输送磷酸二酯酶5抑制剂来增强性功能障碍或低功能治疗的组合物和输送方法。磷酸二酯酶5抑制剂是用于此适应症的化合物类别的一个例子。此类化合物的例子包括他达拉非和伐地那非和西地那非。此外，本发明提供了一种增强溶液、悬浮液和凝胶配方中西地那非浓度的组合物和输送方法，以及静脉、皮内、舌下、鼻内和颊粘膜西地那非输送方法。
• Pharmaceutical composition of sildenafil and a large conductance Ca(2+) activated K+ channels activator
  申请人：LABORATORIOS DEL DR. ESTEVE, S.A.

  公开号：EP1652521A1

  公开（公告）日：2006-05-03

  The present invention refers to a pharmaceutical composition of sildenafil and a large conductance Ca(2+) activated K+ channels activator and its use for the treatment of sexual dysfunction in man and woman, sexual disorders in man, erectile dysfunction or impotence.

  本发明涉及一种由西地那非和一种大电导 Ca(2+) 活化 K+ 通道激活剂组成的药物组合物，及其用于治疗男女性功能障碍、男性性障碍、勃起功能障碍或阳痿的用途。
• Phamaceutical composition comprising a 2,5-dihydroxybenzenesulfonic-compound, a potassium ion channel modulator and a phosphodiesterase type 5 inhibitor
  申请人：LABORATORIOS DEL DR. ESTEVE, S.A.

  公开号：EP1676573A1

  公开（公告）日：2006-07-05

  The present invention relates to a pharmaceutical composition comprising a 2,5-dihydroxybenzenesulfonic compound, a potassium ion channel modulator and a phosphodiesterase type 5 inhibitor, a medicament comprising said pharmaceutical composition as well as the use of said pharmaceutical composition for the manufacture of a medicament.

  本发明涉及一种由 2,5-二羟基苯磺酸化合物、钾离子通道调节剂和 5 型磷酸二酯酶抑制剂组成的药物组合物，一种包含所述药物组合物的药品，以及使用所述药物组合物制造药品。